Since the KRAS mutation might be one initiating genetic event for the development of PC, combinatorial treatment with either KRAS or MEK inhibitors, together with mTORC1/2 inhibitors may result in synergistic cytotoxicity and cell death. This evidence concerns the gene KRAS and pachyonychia congenita.